



Medical Policy

Surgical Left Atrial Appendage Occlusion Devices for Stroke Prevention in Atrial Fibrillation

Table of Contents

- [Policy: Commercial](#)
- [Policy: Medicare](#)
- [Authorization Information](#)
- [Coding Information](#)
- [Description](#)
- [Policy History](#)
- [Information Pertaining to All Policies](#)
- [References](#)

Policy Number: 176

BCBSA Reference Number: 7.01.172 (For Plan internal use only)
NCD/LCD: N/A

Related Policies

Percutaneous Left Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation, [#334](#)

Policy

Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO BlueSM and Medicare PPO BlueSM Members

The use of surgical left atrial appendage occlusion devices, including the AtriClip device, for stroke prevention in individuals with atrial fibrillation undergoing open or thoracoscopic cardiac procedures is considered investigational. [INVESTIGATIONAL](#).

The use of surgical left atrial appendage occlusion devices, including the AtriClip device, for stroke prevention as a stand-alone procedure for stroke prevention in individuals with atrial fibrillation is considered [INVESTIGATIONAL](#).

Prior Authorization Information

Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

Outpatient

- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

| | Outpatient |
|---------------------------------------|--|
| Commercial Managed Care (HMO and POS) | This procedure is performed in the inpatient setting |
| Commercial PPO and Indemnity | This procedure is performed in the inpatient setting |
| Medicare HMO Blue SM | This procedure is performed in the inpatient setting |
| Medicare PPO Blue SM | This procedure is performed in the inpatient setting |

CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

The following codes are included below for informational purposes only; this is not an all-inclusive list.

According to the policy statement above, the following CPT codes are considered investigational for the conditions listed for Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue and Medicare PPO Blue:

CPT Codes

| CPT codes: | Code Description |
|------------|---|
| 33267 | Exclusion of left atrial appendage, open, any method (eg, excision, isolation via stapling, oversewing, ligation, plication, clip) |
| 33268 | Exclusion of left atrial appendage, open, performed at the time of other sternotomy or thoracotomy procedure(s), any method (eg, excision, isolation via stapling, oversewing, ligation, plication, clip) (List separately in addition to code for primary procedure) |
| 33269 | Exclusion of left atrial appendage, thoracoscopic, any method (eg, excision, isolation via stapling, oversewing, ligation, plication, clip) |

Description

Atrial Fibrillation

Nonvalvular atrial fibrillation (AF) is the most common type of cardiac arrhythmia, affecting at least 2.7 million people in the United States. The risk of AF has been found to be lower in Black, Hispanic, and Asian patients relative to White patients, following adjustment for demographic and AF risk factors.^{1,2} AF is typically described according to frequency and duration and includes paroxysmal (duration up to 1 week), persistent (>1 week), long-term persistent (>1 year), or permanent (normal sinus rhythm cannot be restored despite treatment).³ Stroke is the most serious complication of AF. The estimated incidence of stroke in non-treated patients with AF is 5% per year. Despite a lower risk of AF, Black and Hispanic patients have an increased risk of stroke compared with White patients.^{4,5} Although this paradox may be partially attributable to clinical factors (e.g., congestive heart failure, hypertension, type 2 diabetes), Black and Hispanic patients with AF are less likely than White patients to receive stroke prevention therapy.⁶ Stroke associated with AF is primarily thromboembolic, tends to be more severe than the typical ischemic stroke, and causes higher rates of mortality and disability. As a result, stroke prevention is one of the main goals of AF treatment.

Stroke Prevention

The risk for stroke among patients with AF is evaluated using several factors. Two commonly used scores, the CHADS₂ score and the CHA₂DS₂-VASc score are described in Table 1:

Table 1. CHADS₂ and CHA₂DS₂-VASc Scores to Predict Ischemic Stroke Risk in Patients with Atrial Fibrillation

| Letter | Clinical Characteristics | Points Awarded |
|--------|--|----------------|
| C | Congestive heart failure (signs/symptoms of heart failure confirmed with objective evidence of cardiac dysfunction) | 1 |
| H | Hypertension (resting blood pressure >140/90 mmHg on at least 2 occasions or current antihypertensive pharmacologic treatment) | 1 |

| | | |
|----|--|--------------------------------|
| A | Age ≥75 y | 1 (CHADS2) 2 (CHA2DS2-VASc) |
| D | Diabetes (fasting glucose >125 mg/dL or treatment with oral hypoglycemic agent and/or insulin) | 1 |
| S | Stroke or transient ischemic attack (includes any history of cerebral ischemia) | 2 |
| V | Vascular disease (prior myocardial infarction, peripheral arterial disease, or aortic plaque) | 1 |
| A | Age 65-74 y | 1 |
| Sc | Sex category of female (female sex confers higher risk) | 1 |

Adapted from Lip et al (2018)⁷ and January et al (2014)⁸.

Stroke in AF occurs primarily as a result of thromboemboli from the left atrium. The erratic atrial contractions in AF lead to blood stasis in the left atrium, and this low flow state increases the risk for thrombosis. The first-line treatment for stroke prevention in AF is long-term anticoagulation, which has proven efficacy.⁹ Warfarin, a vitamin K antagonist, is the predominant agent in clinical use. Several newer direct oral anticoagulant (DOAC) agents, including dabigatran, rivaroxaban, apixaban, and edoxaban, have received U.S. Food and Drug Administration (FDA) approval for stroke prevention in nonvalvular AF and have demonstrated noninferiority to warfarin in clinical trials. Warfarin requires frequent monitoring and adjustments as well as lifestyle changes; DOACs do not require the frequent monitoring seen with warfarin therapy. While anticoagulation is effective for stroke prevention, it carries an increased risk of bleeding. Reversal agents can be used to counter the effects of life-threatening bleeding in individuals using warfarin or DOAC therapy. Such agents carry their own risk of inducing life-threatening thrombosis. For individuals with AF who have a contraindication to warfarin and DOACs, dual antiplatelet therapy with aspirin and clopidogrel is an option for stroke prevention, though it is less protective than either warfarin or DOACs.

The area of the left atrium with the lowest blood flow in AF, and therefore the highest risk of thrombosis, is the left atrial appendage (LAA). The LAA is a small extension of the left atrium that can vary widely in both size and shape (morphology). LAA morphologies are described according to their appearance and include: the chicken wing, which is the most common morphology and features a prominent bend in the dominant lobe; the cactus, characterized by a dominant central lobe with superior and inferior secondary lobes; the windsock, which features one dominant lobe; and the cauliflower, which is the least common morphology and features numerous lobes with none being dominant. It has been estimated that over 90% of left atrial thrombi occur in the LAA. Surgical removal or exclusion of the LAA is often performed in patients with AF who are undergoing open heart surgery. Surgical techniques to exclude the LAA include resection or occlusion through stapling or clipping.^{9,10}

Percutaneous LAA occlusion is discussed in policy [#334](#)

Summary

Atrial fibrillation (AF) is the most common type of cardiac arrhythmia. Stroke associated with AF is primarily embolic, tends to be more severe than the typical ischemic stroke, and causes higher rates of mortality and disability. As a result, stroke prevention is one of the main goals of AF treatment. Treatment with anticoagulant medications is a first-line approach to stroke prevention in individuals with AF, although occlusion of the left atrial appendage (LAA) may offer a non-pharmacological alternative to anticoagulant medications for those with a contraindication or intolerance to long-term anticoagulant use or with poor anticoagulant adherence. Multiple surgical techniques may be used to excise or occlude the LAA. One device, the AtriClip Left Atrial Appendage Exclusion System, has approval from the U.S. Food and Drug Administration for surgical LAA occlusion for stroke prevention in patients with AF.

Summary of Evidence

For individuals with atrial fibrillation (AF) at increased risk for embolic stroke undergoing left atrial appendage (LAA) occlusion with an AtriClip device concomitant with open or thoracoscopic cardiac surgical procedures, the evidence includes a randomized controlled trial (RCT), a controlled observational study, and case series. Relevant outcomes are ischemic stroke, cardiac events, and mortality. Although evidence from several systematic reviews and a large (N>10,000) observational study found surgical LAA occlusion was associated with a reduction in the risk of stroke without an increase in the risk of adverse events, direct evidence specifically comparing the AtriClip Left Atrial Appendage Exclusion System with anticoagulation, another surgical occlusion method, or no occlusion is limited. LAA occlusion was associated with a reduced risk of stroke versus no occlusion in the Left Atrial Appendage Occlusion Study (LAAOS) III trial, but the trial was not designed to specifically assess the net health benefit of LAA occlusion with an AtriClip device. A retrospective database study that compared the AtriClip device with no occlusion found that AtriClip placement was associated with a lower risk of ischemic stroke, which was not statistically significant, and a reduced risk of thromboembolism that was of marginal statistical significance. Large (N>100) case series of AtriClip device use with 2- to 3-year follow-up reported stroke rates of 1% or fewer in the postoperative period and 2% or fewer in the long-term follow-up. Well-designed RCTs with follow-up of 1 year or more comparing the AtriClip device with anticoagulation, other surgical occlusion methods, and/or no occlusion are needed to provide adequate evidence for assessment of net health benefit. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with AF at increased risk for embolic stroke undergoing LAA occlusion with an AtriClip device as a stand-alone procedure, the evidence includes a controlled observational study and case series. Relevant outcomes are ischemic stroke, cardiac events, and mortality. One small (N=40) industry-sponsored retrospective observational study reported that use of the AtriClip device as a stand-alone procedure resulted in similar outcomes compared to percutaneous LAA occlusion. This evidence is too limited to draw definitive conclusions. Well-designed RCTs with follow-up of 1 year or more comparing stand-alone AtriClip device placement with percutaneous LAA occlusion are needed to provide adequate evidence for assessment of net health benefit. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Policy History

| Date | Action |
|---------|--|
| 10/2024 | Annual policy review. References updated. Policy statements unchanged. |
| 5/2024 | Clarified coding language above code table |
| 10/2023 | Annual policy review. Description, summary, and references updated. Policy statements unchanged. |
| 1/2023 | New medical policy describing investigational indications. Effective 1/1/2023. |

Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

[Clinical Exception Process](#)

[Medical Technology Assessment Guidelines](#)

References

1. Dewland TA, Olgin JE, Vittinghoff E, et al. Incident atrial fibrillation among Asians, Hispanics, blacks, and whites. *Circulation*. Dec 03 2013; 128(23): 2470-7. PMID 24103419
2. Mou L, Norby FL, Chen LY, et al. Lifetime Risk of Atrial Fibrillation by Race and Socioeconomic Status: ARIC Study (Atherosclerosis Risk in Communities). *Circ Arrhythm Electrophysiol*. Jul 2018; 11(7): e006350. PMID 30002066
3. Nesheiwat Z, Goyal A, Jagtap M. Atrial Fibrillation. In: StatPearls. Treasure Island (FL): StatPearls Publishing; November 28, 2021.

4. Gardener H, Sacco RL, Rundek T, et al. Race and Ethnic Disparities in Stroke Incidence in the Northern Manhattan Study. *Stroke*. Apr 2020; 51(4): 1064-1069. PMID 32078475
5. Guo J, Gabriel N, Magnani JW, et al. Racial and Urban-Rural Difference in the Frequency of Ischemic Stroke as Initial Manifestation of Atrial Fibrillation. *Front Public Health*. 2021; 9: 780185. PMID 34805085
6. Tamirisa KP, Al-Khatib SM, Mohanty S, et al. Racial and Ethnic Differences in the Management of Atrial Fibrillation. *CJC Open*. Dec 2021; 3(12 Suppl): S137-S148. PMID 34993443
7. Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. *Chest*. Nov 2018; 154(5): 1121-1201. PMID 30144419
8. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol*. Dec 02 2014; 64(21): e1-76. PMID 24685669
9. Collado FMS, Lama von Buchwald CM, Anderson CK, et al. Left Atrial Appendage Occlusion for Stroke Prevention in Nonvalvular Atrial Fibrillation. *J Am Heart Assoc*. Nov 02 2021; 10(21): e022274. PMID 34668395
10. Rosati F, de Maat GE, Valente MAE, et al. Surgical clip closure of the left atrial appendage. *J Cardiovasc Electrophysiol*. Oct 2021; 32(10): 2865-2872. PMID 34288215
11. U.S. Food and Drug Administration. AtriClip LAA Exclusion System (K172742). https://www.accessdata.fda.gov/cdrh_docs/pdf17/K172742. Accessed June 14, 2024.
12. AtriCure. AtriClip LAA Exclusion System. <https://www.atricure.com/healthcare-professionals/therapies/LAAM/atriclip-exclusion-system>. Accessed June 14, 2024.
13. Ando M, Funamoto M, Cameron DE, et al. Concomitant surgical closure of left atrial appendage: A systematic review and meta-analysis. *J Thorac Cardiovasc Surg*. Sep 2018; 156(3): 1071-1080.e2. PMID 29628346
14. Atti V, Anantha-Narayanan M, Turagam MK, et al. Surgical left atrial appendage occlusion during cardiac surgery: A systematic review and meta-analysis. *World J Cardiol*. Nov 26 2018; 10(11): 242-249. PMID 30510641
15. Ibrahim AM, Tandan N, Koester C, et al. Meta-Analysis Evaluating Outcomes of Surgical Left Atrial Appendage Occlusion During Cardiac Surgery. *Am J Cardiol*. Oct 15 2019; 124(8): 1218-1225. PMID 31474327
16. Friedman DJ, Piccini JP, Wang T, et al. Association Between Left Atrial Appendage Occlusion and Readmission for Thromboembolism Among Patients With Atrial Fibrillation Undergoing Concomitant Cardiac Surgery. *JAMA*. Jan 23 2018; 319(4): 365-374. PMID 29362794
17. Aryana A, Singh SK, Singh SM, et al. Association between incomplete surgical ligation of left atrial appendage and stroke and systemic embolization. *Heart Rhythm*. Jul 2015; 12(7): 1431-7. PMID 25998141
18. Abrisch VA, Narichania AD, Love WT, et al. Left atrial appendage exclusion during mitral valve surgery and stroke in atrial fibrillation. *J Interv Card Electrophysiol*. Dec 2018; 53(3): 285-292. PMID 30267182
19. Blackshear JL, Johnson WD, Odell JA, et al. Thoracoscopic extracardiac obliteration of the left atrial appendage for stroke risk reduction in atrial fibrillation. *J Am Coll Cardiol*. Oct 01 2003; 42(7): 1249-52. PMID 14522490
20. Fu M, Qin Z, Zheng S, et al. Thoracoscopic Left Atrial Appendage Occlusion for Stroke Prevention Compared with Long-Term Warfarin Therapy in Patients With Nonvalvular Atrial Fibrillation. *Am J Cardiol*. Jan 01 2019; 123(1): 50-56. PMID 30385030
21. Inoue T, Suematsu Y. Left atrial appendage resection can be performed minimally invasively with good clinical and echocardiographic outcomes without any severe risk. *Eur J Cardiothorac Surg*. Jul 01 2018; 54(1): 78-83. PMID 29370349
22. Jiang S, Zhang H, Wei S, et al. Left atrial appendage exclusion is effective in reducing postoperative stroke after mitral valve replacement. *J Card Surg*. Dec 2020; 35(12): 3395-3402. PMID 32939788
23. Kewcharoen J, Shah K, Bhardwaj R, et al. Surgical left atrial appendage occlusion in patients with left ventricular assist device. *Pacing Clin Electrophysiol*. Apr 2022; 45(4): 567-570. PMID 35199863
24. Ohtsuka T, Nonaka T, Hisagi M, et al. Thoracoscopic stapler-and-loop technique for left atrial appendage closure in nonvalvular atrial fibrillation: Mid-term outcomes in 201 patients. *Heart Rhythm*. Sep 2018; 15(9): 1314-1320. PMID 29803851

25. Park-Hansen J, Holme SJV, Irmukhamedov A, et al. Adding left atrial appendage closure to open heart surgery provides protection from ischemic brain injury six years after surgery independently of atrial fibrillation history: the LAACS randomized study. *J Cardiothorac Surg.* May 23 2018; 13(1): 53. PMID 29792215
26. Yao X, Gersh BJ, Holmes DR, et al. Association of Surgical Left Atrial Appendage Occlusion With Subsequent Stroke and Mortality Among Patients Undergoing Cardiac Surgery. *JAMA.* May 22 2018; 319(20): 2116-2126. PMID 29800182
27. Toale C, Fitzmaurice GJ, Eaton D, et al. Outcomes of left atrial appendage occlusion using the AtriClip device: a systematic review. *Interact Cardiovasc Thorac Surg.* Nov 01 2019; 29(5): 655-662. PMID 31292605
28. Kurfist V, Mokráček A, Canádyová J, et al. Epicardial clip occlusion of the left atrial appendage during cardiac surgery provides optimal surgical results and long-term stability. *Interact Cardiovasc Thorac Surg.* Jul 01 2017; 25(1): 37-40. PMID 28369643
29. Whitlock RP, Belley-Cote EP, Paparella D, et al. Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke. *N Engl J Med.* Jun 03 2021; 384(22): 2081-2091. PMID 33999547
30. AtriClip Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures (ATLAS). <https://clinicaltrials.gov/ct2/show/NCT02701062>. Accessed June 14, 2024.
31. Soltesz EG, Dewan KC, Anderson LH, et al. Improved outcomes in CABG patients with atrial fibrillation associated with surgical left atrial appendage exclusion. *J Card Surg.* Apr 2021; 36(4): 1201-1208. PMID 33491275
32. Caliskan E, Sahin A, Yilmaz M, et al. Epicardial left atrial appendage AtriClip occlusion reduces the incidence of stroke in patients with atrial fibrillation undergoing cardiac surgery. *Europace.* Jul 01 2018; 20(7): e105-e114. PMID 29016813
33. Kurfist V, Mokracek A, Canadyova J, et al. Effectivity of Left Atrial Appendage Occlusion with AtriClip in 155 Consecutive Patients - Single Center Study. *Cor et Vasa.* August 2017; 59(4): e376-e380.
34. van der Heijden CAJ, Weberndörfer V, Luermans JGLM, et al. Hybrid ablation of atrial fibrillation: A unilateral left-sided thoracoscopic approach. *J Card Surg.* Dec 2022; 37(12): 4630-4638. PMID 36349741
35. Branzoli S, Guarracini F, Marini M, et al. Heart Team for Left Atrial Appendage Occlusion: A Patient-Tailored Approach. *J Clin Med.* Dec 29 2021; 11(1). PMID 35011916
36. Cartledge R, Suwalski G, Witkowska A, et al. Standalone epicardial left atrial appendage exclusion for thromboembolism prevention in atrial fibrillation. *Interact Cardiovasc Thorac Surg.* Mar 31 2022; 34(4): 548-555. PMID 34871377
37. Franciulli M, De Martino G, Librera M, et al. Stand-Alone Thoracoscopic Left Atrial Appendage Closure in Nonvalvular Atrial Fibrillation Patients at High Bleeding Risk. *Innovations (Phila).* 2020; 15(6): 541-546. PMID 33048625
38. Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation.* Jan 02 2024; 149(1): e1-e156. PMID 38033089
39. Saw J, Holmes DR, Cavalcante JL, et al. SCAI/HRS expert consensus statement on transcatheter left atrial appendage closure. *Heart Rhythm.* May 2023; 20(5): e1-e16. PMID 36990925
40. Wyler von Ballmoos MC, Hui DS, Mehaffey JH, et al. The Society of Thoracic Surgeons 2023 Clinical Practice Guidelines for the Surgical Treatment of Atrial Fibrillation. *Ann Thorac Surg.* Jan 27 2024. PMID 38286206